is a neurodegenerative disorder that disrupts a patient’s movement by damaging the central nerve system. The first symptoms begin to appear after age 50, usually beginning with a mild tremor. Symptoms progress over time to include more severe shaking, stiffness, slurred speech, difficulty balancing difficulty walking or standing, and finally delusions and hallucinations. The disease is attributed to a breakdown in neuron communication, which results in difficulties with movement. There are currently no cures.
Alzheimer’s disease is a progressive neurological disease that causes neuron cells to die causing cognitive decline. It is the most common form of dementia. It results in problems with memory and thinking as well as behavior changes that disrupt daily routines. Eventually, the patient is unable to complete basic tasks and cannot live on their own. Learn more about it here
The two neurodegenerative diseases have symptoms that develop as a direct response to the excess of proteins in the brain cells, so the treatment focuses on stopping that ribosomal translation. The investigational drug Posiphen interrupts the translation of the proteins so that they’re not being produced at such a high rate. By disrupting production, the drug manufacturers hope the drug will help maintain healthier cell communication. A previous study on the treatment on mice found the treatment to successfully reduce gut problems due to the lessening of the protein alpha-synuclein, the toxic protein in Parkinson’s patients.
As the drug marches through the clinical barriers, the newest phase includes plans to enroll 68 patients with the two diseases for four week trials across the US. They will study the health of neuron cells and if the drug can minimize the build up of the toxic proteins. They hope the study will show the drug to be both safe and effective at improving neural functioning. In the press release, they explain they also hope to see the effect of the drug